Showing results (21-30 of 64) with videos related to

Sort By:
Pageof 7
Genes & Development|December 14, 2011
Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancerTanaya Shree, Oakley C Olson, Benelita T Elie, et al.
European Journal of Haematology|December 5, 2022
Progressive multifocal leukoencephalopathy in multiple myelomaBrian W Hoeynck, Adam D Cohen, Edward A Stadtmauer, et al.
Biorxiv : the Preprint Server for Biology|May 25, 2026
LVV SMRTcap reveals extensive proviral variation in lentiviral vector-transduced CAR T cellsCatherine W Kaiser, Ghazal S Mehs, Erin M Elliott, et al.
Leukemia|February 15, 2019
RUNX proteins desensitize multiple myeloma to lenalidomide via protecting IKZFs from degradationNan Zhou, Alvaro Gutierrez-Uzquiza, Xiang Yu Zheng, et al.
Transplantation and Cellular Therapy|January 23, 2025
Prolonged Neurologic Symptoms Following Immune Effector Cell-Associated Neurotoxicity Syndrome in Patients With Large B-cell Lymphoma Treated With Chimeric Antigen Receptor-Modified T Cell TherapyLuke Maillie, Sunita D Nasta, Jakub Svoboda, et al.
The Journal of Experimental Medicine|May 5, 2026
Rab5 improves CAR T cell efficacy via reducing fratricide and maintaining surface CAR levelsMeidi Gu, Kaitlin A Read, Vipin Bhardwaj, et al.
Journal of Comparative Effectiveness Research|April 28, 2023
Teclistamab versus real-world physician's choice of therapy in triple-class exposed relapsed/refractory multiple myelomaAmrita Krishnan, Ajay K Nooka, Ajai Chari, et al.
Blood Cancer Discovery|August 26, 2022
Changes in Bone Marrow Tumor and Immune Cells Correlate with Durability of Remissions Following BCMA CAR T Therapy in MyelomaKavita M Dhodapkar, Adam D Cohen, Akhilesh Kaushal, et al.
Biorxiv : the Preprint Server for Biology|February 8, 2024
Human IL-6 fosters long-term engraftment of patient derived disease-driving myeloma cells in immunodeficient miceZainul S Hasanali, Alfred L Garfall, Lisa Burzenski, et al.
Transplantation and Cellular Therapy|May 21, 2023
Survival Outcomes for Patients with Relapsed/ Refractory Aggressive B Cell Lymphomas Following Receipt of High-Dose Chemotherapy/Autologous Stem Transplantation and/or Chimeric Antigen Receptor-Modified T CellsDaniel J Landsburg, Sunita D Nasta, Jakub Svoboda, et al.
Pageof 7